Life-Years Gained From Defibrillator Implantation

Author:

Salukhe Tushar V.1,Dimopoulos Konstantinos1,Sutton Richard1,Coats Andrew J.1,Piepoli Massimo1,Francis Darrel P.1

Affiliation:

1. From the National Heart and Lung Institute (T.V.S., K.D., R.S., M.P., D.P.F.), Imperial College of Science, Technology and Medicine, London, UK; Royal Brompton Hospital (T.V.S., K.D., R.S., M.P.), London, UK; Faculty of Medicine, Sydney University (A.J.C.), Sydney, Australia; and Cardiac Performance Unit (D.F.), Department of Cardiology, St. Mary’s Hospital, London, UK.

Abstract

Background— Although treatment benefit in randomized controlled trials of defibrillators is often summarized by the numbers of lives saved (absolute risk difference), this may not be a good representation of what matters most to patients, namely, the amount of life they should expect to gain from implantation. The estimate of gain in life-years may depend on duration of follow-up. In this study, we examine this dependency. Methods and Results— We estimated, from published data of 8 landmark defibrillator trials, the cumulative benefit in life-years gained at time points from 3 months to 3 years. Because the trial populations, clinical status, and prognosis varied widely between studies, we expressed for each study the benefit at each time point as the proportion of benefit at 3 years. The average dependency of the benefit on duration of follow-up was then calculated. We found that the number of life-years gained from 1 device implantation increases with length of follow-up considered. Importantly, this increase is markedly nonlinear. Within the 3-year span addressable, the benefit rises with the square of time (gain ∞ t 1.94 , R 2 =0.998, P <0.001). Conclusions— Measurable benefit from a defibrillator to patients’ life spans (life-years gained) is dramatically dependent on the time window over which the benefit is assessed. Because the effort of implantation is front loaded, yet benefit grows with time, the choice of an early time point artificially reduces apparent benefit and artificially increases the apparent number needed to treat to prevent an event. These are useful considerations for the formulation of treatment policy (and even for planning of the follow-up phase of clinical trials).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Cited by 59 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Nonparametric inference for time-dependent incremental cost-effectiveness ratios;Statistics in Medicine;2015-07-27

2. Opportunity to Increase Life Span in Narrow QRS Cardiac Resynchronization Therapy Recipients by Deactivating Ventricular Pacing;JACC: Heart Failure;2015-04

3. Reply;Journal of the American College of Cardiology;2014-07

4. Cost-effectiveness of implantable cardioverter-defibrillator in today's world;Indian Heart Journal;2014-01

5. Ischemic Heart Disease;Cardiac Electrophysiology: From Cell to Bedside;2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3